Interleukin-6 Receptor Blockade can Increase the Risk of Nonalcoholic Fatty Liver Disease: Indications From Mendelian Randomization
Background: Interleukin-6 receptor (IL-6R) blockade has been approved for inflammation-associated diseases and whether it is effective in treating non-alcoholic fatty liver disease (NAFLD) is still unknown.Methods: A target-based Mendelian randomization was performed to appraise whether inhibiting t...
Main Authors: | Shuxuan Li, Lanlan Chen, Guoyue Lv |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.905936/full |
Similar Items
-
Causal effects from nonalcoholic fatty liver disease on cholelithiasis: A mendelian randomization study
by: Yin‐Shi Su, et al.
Published: (2024-03-01) -
Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice
by: Ye Eun Cho, et al.
Published: (2023-10-01) -
Ten interleukins and risk of prostate cancer
by: Bing-Hui Li, et al.
Published: (2023-01-01) -
Assessing the causal relationship between genetically determined inflammatory biomarkers and low back pain risk: a bidirectional two-sample Mendelian randomization study
by: Wenhan Li, et al.
Published: (2023-07-01) -
Corrigendum: Assessing the causal relationship between genetically determined inflammatory biomarkers and low back pain risk: a bidirectional two-sample Mendelian randomization study
by: Wenhan Li, et al.
Published: (2023-11-01)